More than a year ago, we wrote a series of articles on Adamas Pharmaceuticals (ADMS); in one of these, we said that ADMS is not a one-trick pony and that Gocovri's eventual label expansion in walking impairment in MS patients will be a far bigger revenue-generator than its existing approval in LID in Parkinson's patients. Gocovri (amantadine) is already FDA approved for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Now that Gocovri has completed enrollment in the phase 3 trial in this new